Index

A
Acute liver failure (ALF), viral hepatitis, 7
Adalimumab, hepatitis B management in immunosuppression patients, 279
Alemtuzumab, hepatitis B management in immunosuppression patients, 280
ALE See Acute liver failure
Antisense RNA
hepatitis D management, 350
hepatitis viruses, 267
APOBEC
covalently closed circular DNA deamination, 38, 86
recruitment, 92
therapeutic targeting, 266–267
woodchuck, 196
Apoptosis, HBx effects, 119–120
AuAg. See Australian antigen
Australian antigen (AuAg), discovery, 4–5, 14

B
Bat hepatitis virus (BtHV), zoonotic infection, 47, 53
B-cell, hepatitis B virus immune response, 146
BtHV. See Bat hepatitis virus

C
Calcium flux, HBx effects, 119
cccDNA. See Covalently closed circular DNA
Cell cycle, HBx effects, 120
Chimpanzee model, hepatitis B virus infection
blood test development, 211–212
chronic infection, 211
historical perspective, 209–212
immune response
clearance mechanisms, 214–220
innate immunity, 213
persistence mechanisms, 215, 218
prospects for study, 220
inoculum size and outcomes, 218
vaccine development, 212–213
Cirrhosis
hepatitis B association, 18–19
hepatitis D management in decompensated cirrhosis patients, 348
Core proteins, hepatitis B virus
capsid assembly, 92–93, 98–99, 101–102
properties, 97
Covalently closed circular DNA (cccDNA)
animal model studies, 35–36, 38
deamination, 38, 86
eradication, 1, 9
formation, 75–77
functions, 91
HBx interactions, 117–118
host evasion, 142
mouse hepatitis B virus infection, 231
persistence, 9, 142
therapeutic targeting, 85–86, 266–267
Cyclin-dependent kinases
HBx effects, 120
hepatitis B virus assembly role, 93

D
Dane particle, 97
DDB1, HBx interactions, 120–121, 267
Delta antigen. See Hepatitis D virus
Delta hepatitis. See Hepatitis D virus
dna methyltransferase, upregulation by HBx, 117
Duck hepatitis B virus. See Hepatitis B virus

E
Endosomal sorting complex (ESCRT), hepatitis B virus particle transport and release, 95–97
ESCRT. See Endosomal sorting complex
Etanercept, hepatitis B management in immunosuppression patients, 279

F
Fas, HBx effects, 119

G
Glomerulonephritis, hepatitis B association, 22
Gorilla hepatitis B virus, phylogeny with other hepatitis viruses, 49
Ground squirrel hepatitis virus. See Hepatitis B virus
Guillain–Barré syndrome, hepatitis B association, 23

H
HBIG. See Hepatitis B immunoglobulin
HBV. See Hepatitis B virus
Index

HBx. See Hepatitis B virus X
HCC. See Hepatocellular carcinoma
HCV. See Hepatitis C virus
HDV. See Hepatitis D virus
Hepatic decompensation, hepatitis B association, 19
Hepatitis B immunoglobulin (HBIG)
  liver transplant patient use, 281
  passive immunization efficacy, 242–243
Hepatitis B virus (HBV)
  animal models
    antiviral therapy, 38–39
    chimpanzee. See Chimpanzee model, hepatitis B virus infection
duck hepatitis B virus, 29–31, 34–35, 37, 81–84
  ground squirrel hepatitis virus, 29, 31
  hepatocellular carcinoma, 39, 184–185
  heron hepatitis B virus, 29
  historical perspective, 29–31
  life cycle of virus, 35
  molecular biology studies
    reverse transcription and priming, 31–35
    second-strand DNA synthesis, 34
  mouse. See Mouse model, hepatitis B virus infection
  protein function elucidation, 36–38
  transient infection, 37–38
  woodchuck. See Woodchuck hepatitis virus
woolly monkey hepatitis B virus, 29
capsid assembly
  allosteric regulation, 101
  biochemistry, 98–100
  core protein determinants, 92–93, 98–99
  kinetics, 100–101
  nucleic acid synergy, 101–102
  overview, 92
capsid structure, 97–98
cell entry
  multistep process, 67–68
  overview, 65–66
  prospects for study, 71–72
  sodium taurocholate cotransporting polypeptide
    role, 65, 67–70
clinical manifestations of infection
  acute disease, 15–16
  chronic disease, 16–18
  extrahepatic manifestations, 22–23
  genotype influences on chronic disease course, 162–165
  HBeAg-negative disease, 17–18
  HBeAg-positive disease, 17
  occult infection, 22
  overview, 7–8
coinfection
  hepatitis C virus, 135
  hepatitis D virus
  acute hepatitis D, 329–331
  chronic disease, 332–333
  helper-independent infection, 331–332
  hepatocellular carcinoma studies, 332–333
  overview, 135–136
  human immunodeficiency virus, 23, 134–135
discovery, 27
envelopment and release
  envelope proteins, 94–95
  maturation signal, 93
  subviral particles, 95
  viral particle transport and release, 95–97
epidemiology
  acute disease, 14
  chronic disease, 14
  genotype distributions, 161–162
  genotype influences, 134
  global prevalence, 130, 132–133
  hepatocellular carcinoma, 136
  high-prevalence populations, 130–131
  indigenous peoples, 131–132
  low-prevalence populations, 131
  mortality, 132
  overview, 129–130, 159–161
genome
  intergenotypic recombination, 162
  structure, 28–29, 77, 109, 160
geographic distribution of genotypes and subgenotypes, 46
history of study, 13–14
host susceptibility studies, 70
immune response overview, 133–134
immune response. See Immune response
origins and evolution
  genomic fossils, 46–47
  genotype and subgenotype roles, 49–50
  human family tree, 54–55
  indigenous population implications for origins, 55–58
  mixed infections and recombination, 50–51
  most recent common ancestor, 45–46
  mutation rate, 50, 84
  prospects for study, 59–60
  theories of origins
    bat origin, 53
    coevolution, 53
    cospeciation, 53
    cross-species transmission, 53
    New World origin, 52
outcomes by age, 242
prevention strategies, 242–243
sequelae of chronic disease. See also Cirrhosis;
  Hepatocellular carcinoma
  cirrhosis, 18–19
  hepatic decompensation, 19
  hepatocellular carcinoma, 19–20, 165–167

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

species specificity, 70–71
surface antigen
discovery, 5
genotype and variant clinical significance, 167–168
prognostic value, 20–21
seroclearance, 21–22
structure, 94–95
vaccine development, 5–6, 28
surface protein domains in infection, 66–67
tissue tropism, 71
transmission, 14–15, 129–130, 242
treatment
cure definitions, 264–265
early intervention rationale, 263–264
failure
management, 261–263
resistance, 259–261
genotype effects on antiviral therapy
interferon therapy, 169–170
nucleoside/nucleotide analogs, 170–171
overview, 168–169
goals and treatment end points, 254
HBeAg-negative patients
duration of therapy, 258–259
on-treatment factors in treatment response prediction, 258
outcomes, 256–257
pretreatment factors in treatment response prediction, 258
HBeAg-positive patients
on-treatment factors in treatment response prediction, 257–258
outcomes, 256
pretreatment factors in treatment response prediction, 257
hepatitis C virus coinfection patients, 283–284
human immunodeficiency virus coinfection patients, 282–283
immunosuppression patients
anti-CD20 therapy effects, 280
anti-CD52 therapy effects, 280
anti-TNF-α therapy effects, 279
exacerbation of chronic disease, 278–279
immunosuppressants in reactivation, 279
prevention and management of reactivation, 280–281
indications, 254–256
liver transplant patients, 281–282
novel drug target identification, 265–269
pregnant patients
efficacy of antiviral drugs, 277–278
infant transmission prevention, 276–277
pregnancy effects on virus course, 276
safety of antiviral drugs, 277
therapeutic targets, 253–254
variant effects on antiviral therapy, 171
vaccination. See Vaccination
virion structure, 97–98
Hepatitis B virus X (HBx)
animal model studies of function, 36–37
apoptosis effects, 119–120
calcium signaling effects, 119
cancer studies, 121
cell cycle effects, 120
covalently closed circular DNA interactions, 117–118
DDB1 interactions, 120–121, 267
ever and promoter interactions, 115–117
functional diversity, 121–122
hepatocellular carcinoma role, 121, 166, 186
innate immunity, 143
overview, 109–111
prospects for study, 123
replication role, 111–112
structure, 111–115
Hepatitis C virus (HCV)
discovery, 7
epidemiology, 2
hepatitis B virus coinfection
management, 283–284
overview, 135
management, 1
milestones in research and treatment, 2–3
Hepatitis D virus (HDV)
assembly, 323–324
clinical manifestations, 8
delta antigen forms, 317, 320–321
diagnosis, 306
discovery, 6–7, 305
epidemiology
prevalence, 306–307
studies
(1980s–1990s, 307–308
Europe, 308–311)
genome
circular conformation and uniqueness, 317–318
genotypes, 317
types of RNA, 316–317
hepatitis B virus coinfection
acute hepatitis D, 329–331
chronic disease, 332–333
helper-independent infection, 331–332
hepatocellular carcinoma studies, 332–333
overview, 135–136
Hepatitis D virus (HDV) (Continued)
host susceptibility studies, 70
origins and evolution, 46, 58–59
pathogenesis, 333–334
posttranscriptional RNA editing, 322–323
replication, 319, 322
ribozymes, 318–320
severity of disease, factors affecting, 333
species specificity, 70–71
surface protein domains in infection, 66–67
tissue tropism, 71
transmission, 305–306

treatment
acute disease, 340–341
chronic disease, 341–345
decompensated cirrhosis patients, 348
interferon combination therapy with nucleoside analogs, 345–346
novel therapies
antisense RNA, 350
hepatocyte entry inhibitors, 348–349
immunotherapy, 350
overview, 348
prenylation inhibitors, 350
nucleoside analogs, 346–348
overview, 339–340
prospects, 350
thymic humoral factor-γ2, 348
thymosin-α1, 348
virion structure, 315–316

Hepatitis E virus (HEV), discovery, 7

Hepatocellular carcinoma (HCC)
animal models, 39–40
hepatitis B
association, 19–20
DNA integration studies, 182–184
epidemiology, 136
genomic alterations and oncogenic pathways, 181–182
genotypes in risk, 165–166
HBx role, 121, 166, 186
variants in risk, 166–167
hepatitis D virus studies, 332–333
immunization in prevention, 247
incidence, 290
mortality, 179
overview, 289–290
risk factors, 180–181
staging
BCLC staging, 291–292
CLIP score, 291
Okuda system, 291
overview, 290–291
selection of staging system, 292
TNM staging, 291
treatment
advanced disease
chemotherapy, 293
immunotherapy, 293–294
novel therapies, 295
oncolytic virus therapy, 294–295
standard frontline therapy, 292–293
early disease
adjuvant therapy after hepatectomy, 297–298
liver transplantation, 298
locoregional ablative therapy, 298–299
surgical resection, 297
transarterial embolization with chemotherapy, 295–296

Hepadnaviridae
comparison of family members, 46–47
phylogenetic tree, 48
Heron hepatitis B virus. See Hepatitis B virus
HEV. See Hepatitis E virus
Hippocrates, hepatitis studies, 3
Historical perspective, viral hepatitis
Australian antigen discovery, 4–5
early characterization, 3–4
screening tools, 5
vaccination and treatment, 5–6
HIV. See Human immunodeficiency virus
Human immunodeficiency virus (HIV), hepatitis B virus coinfection
management, 282–283
overview, 23, 134–135

Immune response
chimpanzee hepatitis B virus infection
clearance mechanisms, 214–220
innate immunity, 213
persistence mechanisms, 215, 218
prospects for study, 220
hepatitis B virus
adaptive immunity
B-cells, 146
regulatory T cells, 148
T-cells, 146–148
Th17 cells, 148
Th22 cells, 148
antigen immunomodulation, 148–149
innate immunity, 142–143
mouse hepatitis B virus infection
acute hepatitis, 231–234
chronic hepatitis, 234–236
natural killer cells, 145–146
natural killer T cells, 145–146
overview, 141–142
replication control, 143–144
therapies, 149–152
vaccination, 150–151
hepatitis D virus, 334
woodchuck hepatitis virus
cloning and characterization of components in
woodchuck, 192–196
T-cell response, 196

Immunization. See Vaccination

Immunosuppression patients with hepatitis B
anti-CD20 therapy effects, 280
anti-CD52 therapy effects, 280
anti-TNF-α therapy effects, 279
exacerbation of chronic disease, 278–279
immunosuppressants in reactivation, 279
prevention and management of reactivation,
280–281

Infliximab, hepatitis B management in
immunosuppression patients, 279

Interferon
chimpanzee hepatitis B virus infection immune
response, 215, 220
hepatitis B virus
genotype effect on therapy, 169–170
immune response, 142–144
treatment outcomes, 256–257
hepatitis C virus management, 1
hepatitis D management
acute disease, 340–341
chronic disease, 341–345
combination therapy with nucleoside analogs,
345–346
history of hepatitis management, 6
hepatitis D virus, 324
hepatocellular carcinoma role, 39

L
Lamivudine, liver transplant patient use, 281–282
Liver cancer. See Hepatocellular carcinoma
Liver transplantation
hepatitis B management in recipients, 281–282
hepatocellular carcinoma treatment, 298
Lonafarnib, hepatitis D management, 350

M
Minus-strand, synthesis, 79
Mouse model, hepatitis B virus infection
acute hepatitis, 231–234
chronic hepatitis, 234–236
historical perspective and types, 229–231

N
Natural killer (NK) cell, hepatitis B virus immune
response, 145–146
Natural killer T (NKT) cell, hepatitis B virus immune
response, 145–146

NF-κB. See Nuclear factor-κB
Nivolumab, hepatocellular carcinoma management, 293
NK cell. See Natural killer cell
NKT cell. See Natural killer T cell
NTCP. See Sodium taurocholate cotransporting
polypeptide
Nuclear factor-κB (NF-κB), HBx effects, 119–120

O
Ofatumumab, hepatitis B management in
immunosuppression patients, 280

P
PAN. See Polyarteritis nodosa
PD-1, therapeutic targeting in hepatocellular
carcinoma, 293
Pembrolizumab, hepatocellular carcinoma
management, 293
Pexa-Vec, hepatocellular carcinoma management,
294–295
pgRNA. See Pregenomic RNA
Pidilizumab, hepatocellular carcinoma management,
293
PKA. See Protein kinase A
PKC. See Protein kinase C
Plus-strand. See Second-strand DNA synthesis
Polyarteritis nodosa (PAN), hepatitis B association, 22
PreCore, animal model studies of function, 36–37
Pregenomic RNA (pgRNA)
digestion, 91
εRNA requirement in packaging and protein
priming, 82
packaging, 78–79
Pregnancy, hepatitis B
efficacy of antiviral drugs, 277–278
infant transmission prevention, 276–277
pregnancy effects on virus course, 276
safety of antiviral drugs, 277
Pre-S, hepatocellular carcinoma mutations, 167, 181
Protein kinase A (PKA), hepatitis B virus assembly
role, 93
Protein kinase C (PKC), hepatitis B virus assembly
role, 93

R
Replication complex, assembly, 78–79
Reverse transcription
animal studies
model, 34–35
overview, 31
priming, 32–34
εRNA requirement in packaging and protein
priming, 82
Index

Reverse transcription (Continued)
genome variability role, 84
host factors in replication, 82–83
reverse transcriptase
human and duck hepatitis B virus comparison, 83–84
structure and function, 81–82
therapeutic targeting, 84–86
Ribavirin
hepatitis C management, 1
hepatitis D management, 346–347
Ribonuclease H, pregenomic RNA digestion, 91
Rituximab, hepatitis B management in immunosuppression patients, 280
RNA interference. See Antisense RNA

S
Second-strand DNA synthesis
animal studies, 34
priming, 80
Small interfering RNA. See Antisense RNA
Sodium taurocholate cotransporting polypeptide (NTCP)
hepatitis B/D cell entry role, 65, 67–70
therapeutic targeting, 265–266, 268–269, 349
SRPK, hepatitis B virus assembly role, 93

T
TACE. See Transarterial embolization with chemotherapy
T-cell
chimpanzee hepatitis B virus infection immune response, 215, 217–220
hepatitis B virus immune response
CD4 and CD8 T-cells, 146–148
regulatory T cells, 148
Th17 cells, 148
Th22 cells, 148
hepatitis D virus response, 334
mouse hepatitis B virus response, 233–235
therapeutic targeting, 268
woodchuck hepatitis virus immune response, 196
vaccines, 197
Telomelysin, hepatocellular carcinoma management, 295
Telomerase reverse transcriptase (TERT), hepatocellular carcinoma mutations, 181–182
TERT. See Telomerase reverse transcriptase
TGF-β. See Transforming growth factor-β
Thymic humoral factor-γ2, hepatitis D management, 348
Thymosin-α1, hepatitis D management, 348

TLRs. See Toll-like receptors
TNF-α. See Tumor necrosis factor-α
Toll-like receptors (TLRs)
therapeutic targeting
hepatitis B, 268
hepatitis D, 350
woodchucks, 194
Transarterial embolization with chemotherapy (TACE), hepatocellular carcinoma management, 295–296
Transforming growth factor-β (TGF-β), hepatitis B virus immune response, 144–145
Tumor necrosis factor-α (TNF-α), HBx effects, 119

V
Vaccination
hepatitis B virus barriers
compliance, 247–248
infant protection duration, 248–249
resources, 247
vaccine failure, 249
chimpanzee hepatitis B virus infection immune response, 212–213
combination of passive and active immunization, 244–245
development, 243
global view, 245–246
immune response, 150–151
passive immunization with HBIG, 242–243
prevention efficacy
active immunization, 243–244
hepatocellular carcinoma, 247
passive immunization with recombinant vaccine, 245
universal immunization, 246–247
surface antigen, 5–6, 28
universal mass immunization program, 245
woodchuck hepatitis virus combination therapy studies, 199
recombinant viral vector immunization, 197–199
T-cell vaccines, 197

WHO. See World Health Organization
WHV. See Woodchuck hepatitis virus
Woodchuck hepatitis virus (WHV)
hepatocellular carcinoma studies, 184–185
history of study, 29–30, 191
immune response
cloning and characterization of components in woodchuck, 192–196

© 2015 by Cold Spring Harbor Laboratory Press. All rights reserved.
Index

T-cell response, 196
T-cell vaccines, 197
T-cell response, persistence, 85
T-cell vaccines, X role, 37
replication studies, 34
Woolly monkey hepatitis B virus. See Hepatitis B virus
species specificity, 192
World Health Organization (WHO), Global Hepatitis
therapy studies
Programme, 136–138
combination therapy studies, 199
prospects for study, 199–202
recombinant viral vector immunization, 197–199
X
X. See Hepatitis B virus X